SCI时时刷

search
+
Are thrombosis, progression, and survival in ET predictable?
Are thrombosis, progression, and survival in ET predictable?
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) that originates from a ...
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia
The TP73 gene is a member of the TP53 family and, due to differential promoter usage, it may be alter...
Clinical features and outcomes in primary nervous system histiocytic neoplasms
Clinical features and outcomes in primary nervous system histiocytic neoplasms
Frequency of isolated nervous system involvement at initial presentation in histiocytic neoplasmsIsolated nervous system i...
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed ...
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control
The dire prognosis of relapsed or refractory (r/r) aggressive T-cell malignancies underscores an urge...
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival ben...
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis ...
Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship
Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship
Childhood acute lymphoblastic leukemia (cALL) survivors suffer early-onset chronic diseases classically associated with ag...
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk diseas...
Performance of newer myeloma staging systems in a contemporary, large patient cohort
Performance of newer myeloma staging systems in a contemporary, large patient cohort
The most widely used staging system for patients with multiple myeloma (MM), the Revised Internationa...
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, et al. Final analysis of a phase II trial of ...
Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory m...
Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma
Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma with sparse tumor B-cells and a favorable progn...
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with definin...
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as...
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexam...
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities
Multiple myeloma (MM) therapeutics have evolved tremendously in recent years, with significant improvement in patient outc...
Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT
Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT
KMT2A-rearranged (KMT2Ar) AML has been categorized as adverse-risk with the exception of t(9;11)(p21....
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxi...
Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
It is well-established that most patients with systemic light chain (AL) amyloidosis have multi-organ involvement and are ...
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
CAR-T cell therapy has led to a significant advance in the treatment of refractory/relapsed diffuse l...
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). A...
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
TP53 mutations (TP53Mut) define the most rapidly fatal AML subtype [1, 2] (Supplementary Fig. S1A). We used AML datasets (...
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
Nucleoporin 98 (NUP98, chromosome 11p15) fusion oncoproteins also called NUP98 rearrangements (NUP98r...
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
BCL-2, a crucial regulator of the mitochondrial apoptotic pathway, maintains myeloblast survival by s...
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
Multiple myeloma (MM) is a plasma cell neoplasm (PCN) [1]. Sensitive and accurate identification of g...
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Competing interests MS reports receiving funding from BeiGene paid to Fred...
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Follicular lymphoma (FL), the most common indolent non-Hodgkin lymphoma, constitutes a paradigm of immune tumor microenvir...
阅读更多
format_indent_increase